vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and WORLD ACCEPTANCE CORP (WRLD). Click either name above to swap in a different company.

WORLD ACCEPTANCE CORP is the larger business by last-quarter revenue ($141.3M vs $121.8M, roughly 1.2× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs -0.6%, a 4.9% gap on every dollar of revenue. On growth, WORLD ACCEPTANCE CORP posted the faster year-over-year revenue change (1.9% vs -1.4%). WORLD ACCEPTANCE CORP produced more free cash flow last quarter ($57.2M vs $517.0K). Over the past eight quarters, Core Laboratories Inc.'s revenue compounded faster (-3.4% CAGR vs -5.8%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Credit Acceptance Corporation is an auto finance company providing automobile loans and other related financial products. The company operates its financial program through a national network of dealer-partners, the automobile dealers participating in the programs. The company operates two programs: the "Portfolio Program" and the "Purchase Program". Through these programs, the company can advance money to automobile dealers in exchange for the right to service the underlying consumer loans a...

CLB vs WRLD — Head-to-Head

Bigger by revenue
WRLD
WRLD
1.2× larger
WRLD
$141.3M
$121.8M
CLB
Growing faster (revenue YoY)
WRLD
WRLD
+3.3% gap
WRLD
1.9%
-1.4%
CLB
Higher net margin
CLB
CLB
4.9% more per $
CLB
4.2%
-0.6%
WRLD
More free cash flow
WRLD
WRLD
$56.6M more FCF
WRLD
$57.2M
$517.0K
CLB
Faster 2-yr revenue CAGR
CLB
CLB
Annualised
CLB
-3.4%
-5.8%
WRLD

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
CLB
CLB
WRLD
WRLD
Revenue
$121.8M
$141.3M
Net Profit
$5.1M
$-911.3K
Gross Margin
Operating Margin
1.5%
-0.7%
Net Margin
4.2%
-0.6%
Revenue YoY
-1.4%
1.9%
Net Profit YoY
-106.8%
EPS (diluted)
$0.11
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
WRLD
WRLD
Q1 26
$121.8M
Q4 25
$138.3M
$141.3M
Q3 25
$134.5M
$134.5M
Q2 25
$130.2M
$132.5M
Q1 25
$123.6M
$165.3M
Q4 24
$129.2M
$138.6M
Q3 24
$134.4M
$131.4M
Q2 24
$130.6M
$129.5M
Net Profit
CLB
CLB
WRLD
WRLD
Q1 26
$5.1M
Q4 25
$4.9M
$-911.3K
Q3 25
$14.2M
$-1.9M
Q2 25
$10.6M
$1.3M
Q1 25
$-154.0K
$44.3M
Q4 24
$7.4M
$13.4M
Q3 24
$11.7M
$22.1M
Q2 24
$9.0M
$9.9M
Gross Margin
CLB
CLB
WRLD
WRLD
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
CLB
CLB
WRLD
WRLD
Q1 26
1.5%
Q4 25
11.5%
-0.7%
Q3 25
15.6%
-1.3%
Q2 25
11.7%
1.5%
Q1 25
3.6%
33.3%
Q4 24
11.0%
11.6%
Q3 24
14.7%
21.3%
Q2 24
12.3%
10.0%
Net Margin
CLB
CLB
WRLD
WRLD
Q1 26
4.2%
Q4 25
3.6%
-0.6%
Q3 25
10.6%
-1.4%
Q2 25
8.2%
1.0%
Q1 25
-0.1%
26.8%
Q4 24
5.7%
9.7%
Q3 24
8.7%
16.8%
Q2 24
6.9%
7.7%
EPS (diluted)
CLB
CLB
WRLD
WRLD
Q1 26
$0.11
Q4 25
$0.11
$-0.19
Q3 25
$0.30
$-0.38
Q2 25
$0.22
$0.25
Q1 25
$0.00
$8.07
Q4 24
$0.15
$2.45
Q3 24
$0.25
$3.99
Q2 24
$0.19
$1.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
WRLD
WRLD
Cash + ST InvestmentsLiquidity on hand
$22.8M
$10.0M
Total DebtLower is stronger
$677.2M
Stockholders' EquityBook value
$275.1M
$351.6M
Total Assets
$587.7M
$1.1B
Debt / EquityLower = less leverage
1.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
WRLD
WRLD
Q1 26
$22.8M
Q4 25
$22.7M
$10.0M
Q3 25
$25.6M
$14.9M
Q2 25
$31.2M
$8.1M
Q1 25
$22.1M
$4.7M
Q4 24
$19.2M
$10.3M
Q3 24
$21.5M
$9.7M
Q2 24
$17.7M
$11.1M
Total Debt
CLB
CLB
WRLD
WRLD
Q1 26
Q4 25
$110.3M
$677.2M
Q3 25
$114.1M
$584.6M
Q2 25
$124.6M
$472.5M
Q1 25
$124.4M
$447.9M
Q4 24
$126.1M
$561.2M
Q3 24
$139.9M
$506.6M
Q2 24
$147.6M
$494.7M
Stockholders' Equity
CLB
CLB
WRLD
WRLD
Q1 26
$275.1M
Q4 25
$266.0M
$351.6M
Q3 25
$271.3M
$365.6M
Q2 25
$261.3M
$427.9M
Q1 25
$253.4M
$439.5M
Q4 24
$246.6M
$428.2M
Q3 24
$250.7M
$417.5M
Q2 24
$240.3M
$422.6M
Total Assets
CLB
CLB
WRLD
WRLD
Q1 26
$587.7M
Q4 25
$584.0M
$1.1B
Q3 25
$591.4M
$1.1B
Q2 25
$602.1M
$1.0B
Q1 25
$591.5M
$1.0B
Q4 24
$585.1M
$1.1B
Q3 24
$600.5M
$1.0B
Q2 24
$597.8M
$1.0B
Debt / Equity
CLB
CLB
WRLD
WRLD
Q1 26
Q4 25
0.41×
1.93×
Q3 25
0.42×
1.60×
Q2 25
0.48×
1.10×
Q1 25
0.49×
1.02×
Q4 24
0.51×
1.31×
Q3 24
0.56×
1.21×
Q2 24
0.61×
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
WRLD
WRLD
Operating Cash FlowLast quarter
$4.0M
$58.0M
Free Cash FlowOCF − Capex
$517.0K
$57.2M
FCF MarginFCF / Revenue
0.4%
40.5%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M
$412.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
WRLD
WRLD
Q1 26
$4.0M
Q4 25
$7.9M
$58.0M
Q3 25
$8.5M
$48.6M
Q2 25
$13.9M
$58.2M
Q1 25
$6.7M
$254.2M
Q4 24
$20.6M
$61.1M
Q3 24
$13.1M
$53.8M
Q2 24
$17.1M
$48.4M
Free Cash Flow
CLB
CLB
WRLD
WRLD
Q1 26
$517.0K
Q4 25
$5.0M
$57.2M
Q3 25
$6.5M
$47.7M
Q2 25
$10.4M
$57.1M
Q1 25
$3.9M
$250.5M
Q4 24
$17.4M
$60.4M
Q3 24
$10.4M
$52.7M
Q2 24
$14.3M
$47.3M
FCF Margin
CLB
CLB
WRLD
WRLD
Q1 26
0.4%
Q4 25
3.6%
40.5%
Q3 25
4.8%
35.5%
Q2 25
8.0%
43.1%
Q1 25
3.1%
151.6%
Q4 24
13.4%
43.6%
Q3 24
7.7%
40.1%
Q2 24
10.9%
36.5%
Capex Intensity
CLB
CLB
WRLD
WRLD
Q1 26
Q4 25
2.1%
0.6%
Q3 25
1.5%
0.7%
Q2 25
2.7%
0.8%
Q1 25
2.3%
2.2%
Q4 24
2.5%
0.5%
Q3 24
2.0%
0.8%
Q2 24
2.2%
0.8%
Cash Conversion
CLB
CLB
WRLD
WRLD
Q1 26
0.77×
Q4 25
1.61×
Q3 25
0.60×
Q2 25
1.31×
43.27×
Q1 25
5.74×
Q4 24
2.78×
4.56×
Q3 24
1.12×
2.43×
Q2 24
1.90×
4.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons